IRIX
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company\'s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex\'s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries.
IRIDEX Corporation (IRIX) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Momentum (C). The rating has held at C+ for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | B- (3.0) | C+ (2.8) | B- (3.0) | C (2.3) | C+ (2.6) | C+ (2.8) |
| 2026-11-05 | B- (3.0) | C+ (2.8) | B- (3.0) | C- (2.0) | C+ (2.7) | C+ (2.7) |
| 2026-10-29 | B- (3.0) | C+ (2.8) | B- (3.0) | C- (1.9) | C+ (2.7) | C+ (2.7) |
| 2026-10-22 | B- (3.0) | C+ (2.8) | B- (3.0) | D+ (1.7) | C+ (2.6) | C+ (2.6) |
| 2026-10-15 | B- (3.0) | C+ (2.8) | B- (3.0) | D+ (1.8) | C+ (2.6) | C+ (2.6) |